While etanercept (a fusion molecule containing the ligand-binding domain of human TNF receptor 2 and IgG1 Fc) was beneficial for patients with low plasma levels of IL6 and interferon (IFN)γ (53, 54), this TNF-α antagonist decoy receptor originally developed for treatment of RA, reportedly exacerbated MG in a patient with RA (55) and also reactivated tuberculosis in some patients (56, 57). The gene discussed is IL6; the disease is myasthenia gravis.